Sirpa Pietikainen

Featured in: Favicon

europa.eu

euronews.com Favicon

biomedcentral.com Favicon

euractiv.com Favicon

euobserver.com Favicon

theparliamentmagazine.eu Favicon

maaseuduntulevaisuus.fi Favicon

europarl.europa.eu Favicon

ctajournal.biomedcentral.com

Articles

Ilmastonmuutoksen haaste ei katoa minnekään

Jun 11, 2024 | verkkouutiset.fi | Sirpa Pietikainen

Sekä Suomessa että Euroopan laajuisesti laitaoikeisto nappasi sunnuntai-illan eurovaaleissa pienemmän vaalivoiton kuin ennen vaaleja ennustettiin. Tulos antaa hyvän pohjan samanlaiselle yhteistyölle keskiryhmien välillä kuin mitä olemme kuluneella vaalikaudella nähneet. Isoissa jäsenmaissa laitaoikeisto jyräsi ennennäkemättömällä tavalla – esimerkiksi Ranskassa äärioikeisto otti murskavoiton ja sai presidentti Emmanuel Macronin julistamaan maassa ennenaikaiset parlamenttivaalit.
Europe has yet to achieve a genuine green industry deal

Apr 22, 2024 | euractiv.com | Sirpa Pietikainen

The EU has clearly set out its aims to lead the world on green growth. Yet only the most optimistic would say the road has been smooth so far. Sirpa Pietikäinen is a Finnish Member of the European Parliament and a member of the European People’s Party. Initiatives including the Energy Performance Buildings Directive and the Nature Restoration Law have been the subject of unusually contentious debate.
MOTION FOR A RESOLUTION on the Commission delegated regulation of 14 March 2024 amending Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods as regards the definition of ‘engineered nanomaterials’ | B9-0225/2024 | Europe

Apr 19, 2024 | europarl.europa.eu | Frédérique Ries |Christel Schaldemose |Sirpa Pietikainen |Anja Hazekamp

B9‑0225/2024 European Parliament resolution on the Commission delegated regulation of 14 March 2024 amending Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods as regards the definition of ‘engineered nanomaterials’ (C(2024)01612 – 2024/2691(DEA)) The European Parliament, –having regard to the Commission delegated regulation of 14 March 2024 amending Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods as regards the...
The growing marginalisation of LGBTIQ people in Uganda

Apr 17, 2024 | europarl.europa.eu | Frédérique Ries |Sirpa Pietikainen |Brando Benifei |Hilde Vautmans

Priority question for written answer P-001092/2024 to the Vice-President of the Commission / High Representative of the Union for Foreign Affairs and Security Policy Rule 138 Sophia in 't Veld (Renew), Brando Benifei (S&D), Diana Riba i Giner (Verts/ALE), Sirpa Pietikäinen (PPE), Vera Tax (S&D), Thijs Reuten (S&D), Petras Auštrevičius (Renew), Tilly Metz (Verts/ALE), Marc Angel (S&D), Isabel Carvalhais (S&D), Frédérique Ries (Renew), Ilana Cicurel (Renew), Alviina Alametsä (Verts/ALE),...
Euroopassa ei ole tarpeen vaipua epätoivoon

Apr 16, 2024 | verkkouutiset.fi | Sirpa Pietikainen

Kulunut vaalikausi EU-parlamentissa on tuonut eteemme haasteita, joita kukaan ei viisi vuotta sitten osannut ennustaa. Pandemia, sota ja talouskriisi ovat värittäneet kriisistä toiseen edennyttä viisivuotiskautta. Tulevasta vaalikaudesta ei ole tulossa yhtään helpompi. Jo nyt osaamme nimetä luontokadon, ympäristökatastrofin ja turvallisuusuhat haasteiksi, jotka määrittävät politiikan suuntaviivoja tulevina vuosina.
SSRI and SNRI medications and the PSSD symptoms they cause

Apr 9, 2024 | europarl.europa.eu | Sirpa Pietikainen

Question for written answer E-001005/2024to the CommissionRule 138Sirpa Pietikäinen (PPE)Mental health challenges are increasing at an alarming rate in the EU. While awareness is growing and access to treatment improving, more potential side effects of medications are also being revealed. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) are the two most common antidepressants.
Shortage of healthcare and long-term care personnel

Mar 26, 2024 | europarl.europa.eu | Sirpa Pietikainen

Question for written answer E-000816/2024to the CommissionRule 138Sirpa Pietikäinen (PPE)Europe’s population is ageing dramatically. The need for quality healthcare and long-term care services is increasing at the same rhythm. The Member States and the EU as a whole need to start looking for answers to the problem before it reaches a critical phase. The EU is already experiencing a critical shortage of healthcare personnel such as nurses.
RECOMMENDATION on the draft Council directive on standards for equality bodies in the field of equal treatment between persons irrespective of their racial or ethnic origin, equal treatment in matters of employment and occupation between persons irrespect

Mar 25, 2024 | europarl.europa.eu | Sirpa Pietikainen

DRAFT EUROPEAN PARLIAMENT LEGISLATIVE RESOLUTION on the draft Council directive on standards for equality bodies in the field of equal treatment between persons irrespective of their racial or ethnic origin, equal treatment in matters of employment and occupation between persons irrespective of their religion or belief, disability, age or sexual orientation, equal treatment between women and men in matters of social security and in the access to and supply of goods and services, and amending...
Microbiome-based solutions for healthier and more sustainable food systems

Mar 18, 2024 | europarl.europa.eu | Sirpa Pietikainen

Question for written answer E-000754/2024to the CommissionRule 138Sirpa Pietikäinen (PPE)Microbiome-based applications offer significant potential for achieving healthier and more sustainable food systems in line with the Green Deal and Farm to Fork Strategy. This includes enhancing agricultural productivity, reducing fertiliser and pesticide use, and preventing diseases in livestock through natural feed additives.
Advancing Global Sustainability: The Urgency of Harmonized ESG Ratings

Jan 11, 2024 | europeanfiles.eu | Sirpa Pietikainen

There is an urgent need for globally standardized ESG measuring, reporting, and ratings to ensure consistency, comparability, and reliability across industries and regions. We require a globally harmonized, science-based, transparent framework based on a comprehensive lifecycle assessment. This methodology should be applicable to both private companies and countries.